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| INTRODUC TI ON
Despite recent advances in cancer treatment, the prognosis of pancreatic cancer is extremely poor as a result of its rapid progression, early metastasis, and limited response to chemotherapy and radiotherapy.
1,2 Therefore, novel therapeutic strategies are needed to improve the prognosis of pancreatic cancer. Pancreatic cancer is characterized by dense fibrotic stroma, called desmoplasia, and pancreatic stellate cells (PSC) are responsible for its generation.
Pancreatic stellate cells are activated by various stimuli from tumorstromal interactions, and transform into myofibroblast-like cells, which express α-smooth muscle actin (α-SMA) as cancer-associated fibroblasts (CAF), 3 and these activated PSC are considered to be one of the main precursors of CAF. 4 CAF are reported to promote malignant behavior of pancreatic cancer cells, such as proliferation, invasion, metastasis, and resistance to chemotherapy or radiotherapy through various cytokines, growth factors, and exosomes that contain microRNA. [5] [6] [7] [8] These findings suggest that targeting CAF and desmoplasia would be a novel strategy to treat pancreatic cancer.
Conophylline (CnP) is a vinca alkaloid extracted from the leaves of the tropical plant, Ervatamia microphylla, and has been shown to promote β-cell differentiation in pancreatic precursor cells. 9 Recently, we reported that CnP suppressed thioacetamide-induced liver fibrosis through the inhibition of hepatic stellate cell activation. 10 Moreover, CnP was found to inhibit PSC and improve islet fibrosis in rat models of type-2 diabetes. 11 In these reports, CnP suppressed α-SMA expression, a marker of stellate cell activation, and type I collagen secretion of PSC and hepatic stellate cells. Therefore, CnP has potential to be developed into an antifibrotic drug. Given the similarity of activated stellate cells and CAF, we hypothesized that CnP can inhibit the activity of CAF, which also express α-SMA, in cancer tissue, and thereby attenuate the cancer-promoting effects of CAF. However, to date, there have been no studies to investigate the effects of CnP on CAF derived from pancreatic cancer tissues.
Therefore, the aim of the present study was to clarify whether CnP could inhibit CAF and suppress desmoplasia in pancreatic cancer. We investigated the effects of CnP on CAF, and the effects of this CAF inhibition on measures of pancreatic cancer malignancy, such as proliferation, invasion, and chemoresistance. We also assessed the effects of CnP and combination therapy with gemcitabine using an in vivo xenograft model co-implanted with CAF and pancreatic cancer cells.
| MATERIAL S AND ME THODS

| Cell cultures and cell isolation
The human PSC line, hPSC5, established from pancreatic cancer tissue, and human pancreatic cancer cell lines, SUIT-2 and SW1990, were used in this study. hPSC5 cells were provided by RIKEN BRC through the National BioResource Project of MEXT, Japan, and SUIT-2 and SW1990 cells were obtained from JCRB Cell Bank (Osaka, Japan) and ATCC (Manassas, VA, USA), respectively. hPSC5 cells were originally isolated by the outgrowth method after collagenase digestion of the resected pancreatic tissue of a patient undergoing surgery for pancreatic cancer. By this method, the isolated PSC are already activated by culture in serum-containing medium and they express typical activated stellate cells and CAF markers including α-SMA, vimentin, type I collagen, and fibronectin. 12, 13 Indeed, the microarray analysis showed that hPSC5 cells express high levels of α-SMA , vimentin, fibronectin and collagens (data not shown). In addition, hPSC5 cells express the stromal markers secreted protein, acidic and rich in cysteine (SPARC) 14 and interleukin (IL)-6, the latter plays a critical role in the interaction between CAF and pancreatic cancer cells. 15 These results indicate that hPSC5 cells showed activated phenotypes, resembling CAF. Additionally, we established primary CAF (CAF1 and CAF2) from surgically resected pancreatic cancer tissues in Gunma University using the method described by Lau et al. 16 We confirmed that CAF showed myofibroblast-like morphology and were positive for α-SMA by western blotting (data not shown 
| Preparation of CnP
The CnP used in this study was isolated and purified from the leaves of E. microphylla and Tabernaemontana divaricata, and prepared as described previously. 10, 17 Briefly, pure CnP was dissolved in methanol and used in vitro; the final concentration of CnP was 0.05-1.0 μg/ mL, with a final methanol concentration of 0.1% (v/v). Crude CnP (containing 22 mg/g pure CnP) was used in vivo, diluted to 2 mg/mL in 0.5% (v/v) Tween-80 solution.
| Protein extraction and western blotting
Total protein was extracted from cells using RIPA buffer (Wako) according to the manufacture's protocol. Western blotting was carried out as described previously. 18, 19 The primary antibodies used in this study were anti-α-SMA mouse monoclonal antibody (A5247; 
| Preparation of conditioned media
After CAF were cultured until 70%-80% confluence in DMEM with 10% FBS, the medium was changed to serum-free DMEM and the cells were cultured for 48 hours. Conditioned medium (CM) was collected as CAF-CM, centrifuged for 10 minutes at 1500 g, and aliquots
were stored at −80°C until use. To evaluate the effect of CnP, the CAF were cultured with serum-free DMEM containing 0.3 μg/mL CnP for 48 hours, and collected as CnP-treated CAF-CM. Both types of CM were used for the following experiments.
| Cell proliferation assay
Cell proliferation assay was carried out using CCK-8 (Dojindo Laboratories, Kumamoto, Japan). CAF and pancreatic cancer cells were seeded at a density of 3000 cells/well in 96-well plates and cultured in DMEM with 10% FBS. After an overnight incubation, the medium was changed to serum-free medium with CnP between 0 and 1.0 μg/mL.
To assess cell proliferation after stimulation with CM, the medium of pancreatic cancer cells was also replaced with CAF-CM or CnP-treated CAF-CM, after overnight incubation. Cell proliferation was evaluated after culture for 48 hours. Absorbance of each well was measured using a spectrophotometer (Bio-Rad, Hercules, CA, USA) at 450 nm with the reference wavelength set at 650 nm.
| Invasion assay
Cell invasion assay was carried out using 24-well Corning BioCoat
Matrigel Invasion Chambers (Corning, Corning, NY, USA). SUIT-2 and SW1990 cells (1 × 10 5 and 7.5 × 10 4 cells/well, respectively) were seeded in the upper chamber with 500 μL serum-free medium, and the lower chamber was filled with 750 μL medium plus 0.3 μg/mL
CnP, CAF-CM, or CnP-treated CAF-CM. After incubation for 48 hours, the cells were fixed and stained with Diff-Quik (Sysmex Corporation, Kobe, Japan). After staining, the cells that had invaded through the pores to the lower surface of the membrane were counted by microscopy. A total of 10 randomly selected fields were evaluated.
| Gemcitabine sensitivity assay
SUIT-2 and SW1990 cells were seeded at a density of 1 × 10 4 cells/ well in 96-well plates in 100 μL DMEM with 10% FBS. After 24 hours, the medium was changed to serum-free medium, CAF-CM, or CnPtreated CAF-CM, and the cells were treated with various concentrations of gemcitabine (0, 1, 10, or 100 nmol/L) for 48 hours. Cell viability was evaluated using CCK-8 assays (Dojindo Laboratories), as described above. Gemcitabine was purchased from Selleck Chemicals (Houston, TX, USA).
| Ultracentrifugation
Ultracentrifugation was carried out as previously described. 20 Briefly, CAF-CM was ultracentrifuged at 110 000 g for 70 minutes at 4°C. The supernatant was collected after the first centrifugation.
The pellets were washed with 11 mL PBS, ultracentrifuged again, and then resuspended in serum-free DMEM. 
| Cytokine array and ELISA
| RNA extraction and RT-qPCR
Cancer-associated fibroblasts were incubated for 48 hours with and without 0.3 μg/mL CnP treatment. Total RNA was extracted using miRNeasy Mini Kit (Qiagen, Hilden, Germany) and quantified using an ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RT-qPCR was carried out as described previously. 21 The following primers Inc., Tokyo, Japan). We compared the proliferation rate between SUIT-2 cells alone and SUIT-2 + hPSC5 cells. We also analyzed the effects of CnP alone or in combination with gemcitabine in the SUIT-2 + hPSC5 group. One week after implantation, we randomly divided mice into four groups: control; CnP; gemcit- 
| In vivo experiments
| Immunohistochemistry and Sirius red staining
Immunohistochemistry was carried out on tumor samples as previously described. 22 Primary antibodies were as follows: mouse mon- 
| Statistical analysis
| RE SULTS
| Cancer-associated fibroblasts promote cancer proliferation and invasion
To confirm the effect of CAF on cancer progression, we evaluated cancer proliferation and invasion using CM from CAF. CM from hPSC5 cells promoted cancer cell proliferation, and similar results were obtained using CM from the primary fibroblasts, CAF1 and CAF2 ( Figure 1A ). Moreover, although the invasion-enhanced effect of CAF1 and CAF2 was small compared with that of hPSC5, the CM from hPSC5, CAF1, and CAF2 cells promoted the invasive ability of SUIT-2 cancer cells ( Figure 1B) . Because of slow growth, the amount of secretion factors of CAF1 and CAF2 was considered to probably be small compared with that of hPSC5. These results suggest that CAF support cancer progression, and that the suppression of CAF is a potential therapeutic target for pancreatic cancer treatment.
| Conophylline suppresses the activity of CAF
To 
| Conophylline inhibits the stimulatory effects of CAF on pancreatic cancer cells
To determine the effects of CnP-mediated inhibition of CAF on pancreatic cancer cells, we investigated pancreatic cancer cell proliferation, invasion, and chemosensitivity using CM from CnP-treated fibroblasts. The proliferation-enhancing effects of hPSC5-CM were eliminated by CnP treatment of the hPSC5 cells and, further, similar results were obtained using primary CAF ( Figure 3A) . Similarly, CnP treatment of fibroblasts decreased the ability of their CM to enhance pancreatic cancer cell invasiveness ( Figure 3B , Figure   S1B ). We confirmed that there was no significant direct effect of low concentrations of CnP on the invasiveness of pancreatic cancer cells ( Figure S1A ). Moreover, CAF-CM decreased the sensitivity of pancreatic cancer cells to gemcitabine; however, this enhanced gemcitabine resistance was attenuated by CnP treatment of CAF ( Figure 3C ). Moreover, similar results were also obtained in SW1990
( Figure S2 ). These results suggest that CnP suppresses secretion of factors from CAF that are involved in cancer progression.
| Conophylline decreases the cytokines produced by CAF that are involved in cancer progression
To assess the factors by which CnP suppresses CAF, we evaluated soluble factors, such as cytokines, and particulate factors, such as exosomes containing microRNA, by using ultracentrifugation. Supernatants after ultracentrifugation showed the same characteristics as the original solutions. In contrast, the resuspended pellets did not show significant effects on the pancreatic cancer cells ( Figure 4A ). These results suggest that CnP exerts its activity through soluble factors such as cytokines produced by CAF.
Next, we analyzed a cytokine array to investigate the differences between CAF-CM and CnP-treated CAF-CM. Although various cytokines were suppressed by CnP treatment, IL-6, IL-8, CCL2, and CXCL12 were decreased remarkably ( Figure 4B ).
Moreover, we confirmed that these cytokines were also suppressed at the mRNA level by RT-qPCR ( Figure 4C ). In fact, the concentration of IL-6, IL-8 and CCL2 decreased with CnP treatment ( Figure S3 ). These results indicate that CnP inhibits tumorstromal interactions by suppressing the synthesis and secretion of paracrine factors from CAF, particularly IL-6, IL-8, CCL2, and CXCL12.
| Cancer-associated fibroblasts promote tumor proliferation and desmoplastic formation in an in vivo xenograft model
To indicate whether hPSC5 cells are activated when they are 
| Conophylline reduces desmoplasia of tumors consisting of SUIT-2 + CAF, and combination therapy with gemcitabine markedly inhibits tumor proliferation
To evaluate the possibility of using CnP alone or in combination with gemcitabine as a therapeutic tool, we investigated the ef- Figure 6A,B) . Additionally, we evaluated adverse events associated with treatment. There were no significant differences among the groups regarding body weight loss and organ toxicity ( Figure S5 ).
These results indicate that CnP suppresses desmoplasia of pancreatic cancer, and combination therapy with gemcitabine has synergic effects during pancreatic cancer treatment.
| D ISCUSS I ON
Herein, we have shown that CAF promote pancreatic cancer malignancy in vitro and in vivo, and that CnP suppresses the ability of CAF to enhance pancreatic cancer cell activity. We also showed that creted by CAF has been actively investigated. 26 Antifibrotic drugs are thought to be candidates for targeting CAF because of their ability to suppress fibroblast activity. Actually, recent studies have shown that pirfenidone and the multi-kinase inhibitor, nintedanib, which are drugs to treat idiopathic pulmonary fibrosis, can inhibit cancer progression through suppression of CAF in pancreatic cancer, 27 breast cancer, 28 and lung adenocarcinoma. 29 It was reported that pirfenidone and nintedanib suppressed TGF-β signaling and production of extracellular matrix components in tumor-stromal interactions. Thus, targeting CAF themselves is a promising therapeutic strategy for cancer treatment. , and CXCL12. mRNA expression levels were quantified by RT-qPCR and were normalized to 18S rRNA levels. *P < .05 (vs control)
In the present study, we showed that CnP suppressed the activities of CAF, and significantly inhibited the synthesis and production of various cytokines, especially IL-6, IL-8, CCL2, and CXCL12. These factors play important roles in the tumor microenvironment in pancreatic cancer. 4, 15, 30 IL-6 secreted by CAF was reported to induce the invasiveness of pancreatic cancer cells through STAT3 signal activation, 31 and the inhibition of IL-6 signaling significantly reduced tumor proliferation in a pancreatic cancer xenograft model. 32 Additionally, IL-8 derived from CAF was reported to promote pancreatic cancer invasion and metastasis. 33 Moreover, CCL2 and CXCL12 were reported to be associated with cancer progression and resistance to radiotherapy, as well as resistance to gemcitabine chemotherapy in pancreatic cancer cells. [34] [35] [36] [37] [38] In the current study, similar to these previous reports, CAF-CM, which abundantly contained these cytokines, promoted pancreatic cancer progression and enhanced chemoresistance to gemcitabine. However, CnP-treated CAF-CM eliminated the ability of CAF to enhance the malignant potential and chemoresistance of pancreatic cancer cells. Therefore, the antitumor effects of CnP were considered to be derived from the inhibition of stromal activity by suppressing the synthesis and production of various cytokines, such as IL-6, IL-8, CCL2, and CXCL12.
We previously reported that CnP suppressed liver fibrosis induced by thioacetamide through the suppression of hepatic stellate cells. 10 Similarly, in the present study, CnP suppressed the desmo- Although the detailed mechanisms of CnP remain unclear, a previous report showed that CnP inhibits cAMP-responsive element binding protein (CREB) activation. 42 CREB is a crucial transcription factor, which regulates a wide range of biological processes to orchestrate proper cell differentiation and cell growth. 43, 44 Moreover, CREB has previously been shown to regulate inflammatory responses by directly regulating gene transcription of proinflammatory genes, such as IL-6 and TNF-α, 45 and CREB silencing has been shown to reduce the levels of IL-6, IL-8, and CCL2 in malignant mesothelioma cells. 46 In contrast, another report showed that CREB promoted hepatic fibrosis through the transactivation of TGF-β expression in rats. 47 Thus, there is a possibility that CREB is a key factor involved in the activity of CnP. We confirmed that TGF-β expression of CAF was decreased by CnP treatment ( Figure S6 ). Thus, although CnP might affect TGF-β signaling, further studies are clearly needed to identify the mechanism of CnP activity.
It is important to validate the results of in vivo xenograft experiments with established CAF; however, the growth speed of established CAF was very slow, and we did not immortalize CAF.
Therefore, we could not obtain a sufficient number of established CAF for use in in vivo experiments. There are some studies where immortalized CAF have been used in in vivo experiments with cancer cells. 5 However, when immortalized CAF is used in vivo experiments with cancer cells, it is unclear whether it is appropriate as an actual microenvironment of tumor. The origins and homology of CAF are still controversial. 48 However, some studies have reported that a major source of CAF in pancreatic cancer is PSC. 49, 50 Therefore, it is difficult to distinguish CAF from PSC. In general, CAF show myofibroblast-like shaped cells and express α-SMA. hPSC5 cells (PSC) used in the present study also showed similar characteristics; they were established from pancreatic cancer tissue. In this milieu, we used hPSC5 as CAF, which is a limitation of the present study. 
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